CRNX

Business Context and Reporting Period

Company: Crinetics Pharmaceuticals, Inc. (CRNX)
Filing Type: Form 8-K (Current Report)
Date: June 26, 2025
Event: The Company hosted an in-person and virtual Research and Development Day (R&D Day) in New York to present updates on its early-stage pipeline assets, preclinical data, and portfolio strategy.

Key Financial Metrics

This filing is a disclosure of a corporate event and does not contain financial statements. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Pipeline Updates

The R&D Day presentation provided significant preclinical updates on three key assets:

• CRN12755 (TSHR Antagonist): Intended for Graves' disease (hyperthyroidism and Thyroid Eye Disease). Preclinical data showed decreased TSAb-stimulated thyroid hormone (T4) in rat models and reduced hyaluronic acid and IL-6 production in patient-derived fibroblasts. The Company outlined a clinical development strategy including key biomarkers for the upcoming Phase 1 trial.
• CRN10329 (SST3 Agonist): Identified as the lead candidate for autosomal dominant polycystic kidney disease (ADPKD). Data indicated decreased cystic index, cellular proliferation, and kidney weight in mouse models. The presentation highlighted consistent SST3 expression in cyst-lining cells in ADPKD.
• CRN09682 (NDC Platform): A nonpeptide drug conjugate for neuroendocrine tumors (NETs). Data demonstrated potency, selectivity, and internalization. In mouse models, the drug cleared from plasma within 24 hours while the active payload persisted in tumors for at least 240 hours. The asset induced anti-tumor activity without body weight loss.

Guidance, Outlook, and Risks

Clinical Trial Design (BRAVESST2): The Company detailed the Phase 1/2 study for CRN09682 targeting metastatic or locally advanced SST2-positive neuroendocrine tumors.

• Phase 1: Dose escalation with 3-6 patients per cohort to determine the minimum tolerated dose.
• Phase 2: Dose expansion based on Phase 1 data to confirm tumor sub-types.
• Enrollment: The Company expects to enroll up to 150 participants across both phases.

Risks: The filing contains forward-looking statements regarding pipeline development and trial enrollment. Actual results may differ materially due to risks described in the Company's Form 10-K (year ended Dec 31, 2024) and Form 10-Q (quarter ended March 31, 2025). The Company does not plan to update these statements publicly except as required by law.

Investor Verification Checklist

• Review the attached slide presentation (Exhibit 99.1) for detailed preclinical data on CRN12755, CRN10329, and CRN09682.
• Monitor the initiation and enrollment progress of the BRAVESST2 Phase 1/2 trial for CRN09682.
• Verify the timeline for the Phase 1 trial of CRN12755 for Graves' disease.
• Consult the most recent Form 10-K and 10-Q for current financial liquidity and cash runway, as this 8-K does not contain financial data.